Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI Palantir Fixed Tech100 Index (KPLTT100)
3/24/2026, 12:00:00 AM
Japan's Ministry of Health, Labour and Welfare (MHLW) approved Dupixent for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), marking the drug's seventh approved indication in Japan. Medium importance reflects an estimated price impact of 5% or more due to market expansion.
Korean Translation
일본 후생노동성(MHLW)이 중등도-중증 성인 수포성 유사천포창(BP) 치료제로 듀피젠트(Dupixent)를 승인함. 이는 일본에서 7번째로 승인된 적응증임. 시장 확대에 따라 5% 이상의 주가 영향이 예상되어 중간 중요도로 평가함.
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
Credo Technology Group Holding Ltd (CRDO) · Earnings Release
Next earnings release for Q4 fiscal 2026 on June 1, 2026, scheduled.
6/1/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA PDUFA action date for the subcutaneous formulation of LEQEMBI for treatment initiation in early Alzheimer's disease is scheduled. This regulatory milestone is estimated to have a medium impact on stock price.
5/24/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Biogen's Q1 2026 earnings release is expected around this date, based on past reporting schedules. Earnings releases typically result in moderate price volatility.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to report its Q1 2026 earnings on May 7, 2026, with analysts forecasting an EPS of approximately -$0.55. Market impact is estimated at ≥1% as earnings dates are routine; scheduled.
5/7/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q1 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM